Formulation Development
argenx & Halozyme Enter Global Collaboration & License Agreement
argenx and Halozyme Therapeutics, Inc. recently announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE drug delivery technology to…
West Annouces Significant Agreements With Swissfillon & scPharmaceuticals
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
uniQure Announces First Patient Treated in Pivotal Trial
uniQure N.V. recently announced it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Meridian Launches New Range of Lyo-Ready PCR Mixes
Meridian Bioscience, Inc. recently announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR.
Spero Therapeutics Announces Initiation of Clinical Trial
Spero Therapeutics, Inc recently announced it has initiated a Phase 1 clinical trial of SPR720, an orally administered antimicrobial agent being developed for the treatment…
Hitachi Chemical to Acquire apceth Biopharma
Hitachi Chemical Advanced Therapeutics Solutions, LLC recently announced an agreement by which apceth Biopharma GmbH will join Hitachi Chemical’s PCT global services platform. apceth Biopharma…
Fortress Biotech Announces Strategic Partnership With Alexion
Fortress Biotech, Inc. recently announced that Caelum Biosciences, Inc. has signed a strategic agreement with Alexion Pharmaceuticals, Inc. to advance the development of CAEL-101 for…
Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial
Evelo Biosciences, Inc. recently announced the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination…
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial
Dicerna Pharmaceuticals, Inc recently announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the company’s investigational GalXCTM-based therapy…
AbbVie’s Immunology Pipeline Will Protect it From Biosimilar Erosion
Although AbbVie is feeling the impact of Humira biosimilar launch in Europe, its strong immunology pipeline is likely to protect its hold on the plaque psoriasis (PsO) and rheumatoid arthritis (RA) markets, according to GlobalData, a leading data and analytics company.
Seelos Therapeutics Announces Successful Completion of Merger With Apricus Biosciences
Seelos Therapeutics, Inc. recently announced the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics,…
Basilea Announces Collaboration With Roche to Study Derazantinib & Atezolizumab
Basilea Pharmaceutica Ltd. recently announced it entered into a collaboration with Roche to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab…
Proteon Therapeutics Announces Publication of Results From Phase 3 Clinical Trial
Proteon Therapeutics Inc. recently announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase.…
Dipharma Announces FDA Acceptance of ANDA of Generic
Dipharma S.A. recently announced that the US Food and Drug Administration (FDA) accepted its nitisinone abbreviated new drug application (ANDA) for review. Nitisinone is a…
Attune Pharmaceuticals Announces $23-Million Financing
Attune Pharmaceuticals, Inc. recently announced the completion of a $23 million Series B financing. Venrock Healthcare Partners led the financing joined by new investor LifeSci…
Hovione Issues $50-Million Bond; Embarks on New Phase of Capital Expansion
Hovione recently announced it issued a bond of $50 million dollars maturing in 2033. The bond was arranged and subscribed by Banco BPI, S.A.
Q BioMed Technology Partner Mannin Research Enters Collaboration With McMaster University
Q BioMed Inc., a biotechnology acceleration company, recently announced its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.
Orion Biotechnology Reports Positive Results for Preclinical Study
Orion Biotechnology Canada Ltd. recently announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c…
Menlo Therapeutics Granted Breakthrough Therapy Designation
Menlo Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for serlopitant for the treatment of pruritus associated with prurigo nodularis (PN).…
Auris Medical Provides Update on Intranasal Betahistine Programs
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and CNS disorders, recently provided an…
